119 related articles for article (PubMed ID: 28891044)
1. Considerations for Evaluating Treatment Effects From Randomized Clinical Trials.
Ruberg SJ; Akacha M
Clin Pharmacol Ther; 2017 Dec; 102(6):917-923. PubMed ID: 28891044
[TBL] [Abstract][Full Text] [Related]
2. Disentangling estimands and the intention-to-treat principle.
Leuchs AK; Brandt A; Zinserling J; Benda N
Pharm Stat; 2017 Jan; 16(1):12-19. PubMed ID: 27910217
[TBL] [Abstract][Full Text] [Related]
3. Intention-to-treat and transparency of related practices in randomized, controlled trials of anti-infectives.
Beckett RD; Loeser KC; Bowman KR; Towne TG
BMC Med Res Methodol; 2016 Aug; 16(1):106. PubMed ID: 27557676
[TBL] [Abstract][Full Text] [Related]
4. The use of the intention-to-treat principle in nursing clinical trials.
Polit DF; Gillespie BM
Nurs Res; 2009; 58(6):391-9. PubMed ID: 19918150
[TBL] [Abstract][Full Text] [Related]
5. Rationale for randomized controlled trials and for intention-to-treat analysis in transfusion medicine: are they one and the same?
Vamvakas EC
Vox Sang; 2008 Oct; 95(3):165-73. PubMed ID: 19121180
[TBL] [Abstract][Full Text] [Related]
6. Intention to treat and per protocol analysis in clinical trials.
Tripepi G; Chesnaye NC; Dekker FW; Zoccali C; Jager KJ
Nephrology (Carlton); 2020 Jul; 25(7):513-517. PubMed ID: 32147926
[TBL] [Abstract][Full Text] [Related]
7. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say?
Gravel J; Opatrny L; Shapiro S
Clin Trials; 2007; 4(4):350-6. PubMed ID: 17848496
[TBL] [Abstract][Full Text] [Related]
8. Estimands for overall survival in clinical trials with treatment switching in oncology.
Manitz J; Kan-Dobrosky N; Buchner H; Casadebaig ML; Degtyarev E; Dey J; Haddad V; Jie F; Martin E; Mo M; Rufibach K; Shentu Y; Stalbovskaya V; Sammi Tang R; Yung G; Zhou J
Pharm Stat; 2022 Jan; 21(1):150-162. PubMed ID: 34605168
[TBL] [Abstract][Full Text] [Related]
9. Synergies From Integrating Randomized Controlled Trials and Real-World Data Analyses.
Najafzadeh M; Gagne JJ; Schneeweiss S
Clin Pharmacol Ther; 2017 Dec; 102(6):914-916. PubMed ID: 29034448
[TBL] [Abstract][Full Text] [Related]
10. Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study.
Abraha I; Cherubini A; Cozzolino F; De Florio R; Luchetta ML; Rimland JM; Folletti I; Marchesi M; Germani A; Orso M; Eusebi P; Montedori A
BMJ; 2015 May; 350():h2445. PubMed ID: 26016488
[TBL] [Abstract][Full Text] [Related]
11. Precise definitions of some terminology for longitudinal clinical trials: subjects, patient populations, analysis sets, intention to treat, and related terms.
Helms RW
Pharm Stat; 2016 Nov; 15(6):471-485. PubMed ID: 27620652
[TBL] [Abstract][Full Text] [Related]
12. Analyzing phase III studies in hospice/palliative care. a solution that sits between intention-to-treat and per protocol analyses: the palliative-modified ITT analysis.
Currow DC; Plummer JL; Kutner JS; Samsa GP; Abernethy AP
J Pain Symptom Manage; 2012 Oct; 44(4):595-603. PubMed ID: 22819439
[TBL] [Abstract][Full Text] [Related]
13. Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials.
Wang SJ; O'Neill RT; Hung HJ
Clin Trials; 2010 Oct; 7(5):525-36. PubMed ID: 20595242
[TBL] [Abstract][Full Text] [Related]
14. Handling missing data in RCTs; a review of the top medical journals.
Bell ML; Fiero M; Horton NJ; Hsu CH
BMC Med Res Methodol; 2014 Nov; 14():118. PubMed ID: 25407057
[TBL] [Abstract][Full Text] [Related]
15. The attributable estimand: A new approach to account for intercurrent events.
Darken P; Nyberg J; Ballal S; Wright D
Pharm Stat; 2020 Sep; 19(5):626-635. PubMed ID: 32198954
[TBL] [Abstract][Full Text] [Related]
16. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials.
Sussman JB; Hayward RA
BMJ; 2010 May; 340():c2073. PubMed ID: 20442226
[TBL] [Abstract][Full Text] [Related]
17. Defining estimands using a mix of strategies to handle intercurrent events in clinical trials.
Qu Y; Shurzinske L; Sethuraman S
Pharm Stat; 2021 Mar; 20(2):314-323. PubMed ID: 33098267
[TBL] [Abstract][Full Text] [Related]
18. Analysis and design of repeated measures in clinical trials using summary statistics.
Ogenstad S
J Biopharm Stat; 1997 Nov; 7(4):593-604. PubMed ID: 9358331
[No Abstract] [Full Text] [Related]
19. Statistical principles for clinical trials.
Kay R
J Int Med Res; 1998; 26(2):57-65. PubMed ID: 9602983
[TBL] [Abstract][Full Text] [Related]
20. Why estimands are needed to define treatment effects in clinical trials.
Keene ON; Lynggaard H; Englert S; Lanius V; Wright D
BMC Med; 2023 Jul; 21(1):276. PubMed ID: 37501156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
